TORNTPHARM Q1 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,591 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
₹791 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharmaceuticals delivered a solid Q1 FY24 with 10% revenue growth to INR 2,591 crores and 30.5% EBITDA margin. India remains the star, growing 14.5% (16% ex-NLEM impact) and outperforming IPM at 9% vs 4% market growth. Curatio integration is ahead of schedule, delivering 7% margin improvement versus pre-acquisition with further upside visible. Brazil saw underlying 12% CC growth (17% INR) despite dispatch delays; Germany recovered with 21% YoY growth from tender wins. US remained stable at INR 293 crores with Bileshwarpura onco facility now FDA-cleared and first product commercialized in July. Gross margin hit multi-quarter high of 25%, driven by branded mix, price increases, and H2FY23 cost efficiencies. Management targets maintaining 30%+ margins rest of year with 75-100bps annual improvement trajectory. Key risks include pending FDA responses on Indrad plant and Dahej EIR, plus muted acute volumes affecting gastro business seasonally.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects current EBITDA margin levels (30.5%) to be maintained for rest of FY24 with further improvement possible from Curatio synergies and operating leverage.
- Branded segment (72-73% of revenues) benefits from annual price increases and operating leverage. With no negatives from generics, 75-100 basis points year-on-year improvement is typical.
- Brazil traditionally has stronger H2 with Q3/Q4 seeing larger proportions due to pre-Christmas sales and April price changes. 6 total branded launches planned in CNS and cardio with 5 remaining after Q1 launch.
- New tender wins from Q1 will start contributing in Q4 FY24 given 6-month lag between tender wins and sales commencement. Q2 and Q3 expected stable before Q4 uptick.
Risks flagged
- Dahej plant EIR response expected September; management optimistic given only 2 relatively insignificant observations. Indrad plant re-inspection date not yet communicated by FDA. Until clearances, US portfolio remains niche and profitable focus.
- Dahej approvals face 'big queue' at FDA. Revlimid launch timing unclear—late entrant with settlement terms undisclosed. Management explicitly deprioritized US as capital allocation target versus India/branded emerging markets.
- Novo Nordisk has undertaken inventory rationalization since Q4, impacting Torrents B2B insulin manufacturing revenues. Expected to recover in about a quarter, but near-term headwind to 'others' segment.
- Q1 acute sales weaker across most datasets. Torrents ~INR 1,000 crore gastro business impacted by seasonality, though chronic business grew double digits. Recovery expected in coming months.
Key quotes
- Our volume traction is ahead of the market. Our internal volume trend is positive. Our overall growth numbers, when you look at either the reported or the underlying growth, are close to 16%, so obviously, volume will be positive there.
- This level [30.5% EBITDA margin] should be maintained for the rest of the year, for sure. Over and above that, there's some amount of improvement can still come.
- Our key priorities remains our expansion in the branded generics market. All in all, we have added about close to 100 reps in the last 18 months. It's not going to be a disproportionate share of investment towards the US.
Research modules